| Literature DB >> 32219505 |
Maija Lindgren1, Minna Holm2, Niina Markkula3, Tommi Härkänen4, Faith Dickerson5, Robert H Yolken6, Jaana Suvisaari2.
Abstract
Common infectious agents, such as Toxoplasma gondii (T. gondii) and several human herpes viruses, have been linked to increased risk of self-harm. The aim of this study was to investigate the associations between self-harm and seropositivity to T. gondii, Epstein-Barr virus (EBV), Herpes Simplex virus Type 1 (HSV-1), and Cytomegalovirus (CMV). IgM and IgG antibodies to these infections were measured in the Health 2000 project nationally representative of the whole Finnish adult population, and 6250 participants, age 30 and over, were followed for 15 years via registers. In addition, lifetime suicidal ideation and suicide attempts based on medical records and interview were assessed within a subsample of 694 participants screened to a substudy for possible psychotic symptoms or as controls. Among the 6250 participants, 14 individuals died of suicide and an additional 4 individuals had a diagnosis of intentional self-harm during follow-up. Serological evidence of lifetime or acute infections was not found to be associated with these suicidal outcomes. However, in the subsample, those seropositive for CMV had fewer suicide attempts compared to those seronegative, adjusting for gender, age, educational level, childhood family size, regional residence, CRP, and screen status (OR for multiple attempts = 0.40, 95% confidence interval 0.20‒0.83, p = 0.014). To conclude, common infections were not associated with risk of death by suicide or with self-harm diagnoses at a 15-year follow-up in the general population sample. Our finding of an increased number of suicide attempts among persons seronegative for CMV calls for further research.Entities:
Keywords: Cytomegalovirus (CMV); Epstein–Barr virus (EBV); Herpes; Herpes simplex virus 1 (HSV-1); Suicide attempt; Toxoplasma gondii
Mesh:
Substances:
Year: 2020 PMID: 32219505 PMCID: PMC7474710 DOI: 10.1007/s00406-020-01120-3
Source DB: PubMed Journal: Eur Arch Psychiatry Clin Neurosci ISSN: 0940-1334 Impact factor: 5.270
Fig. 1The participants of the register follow-up and the PIF subsample
Baseline characteristics and prevalences of the antibodies in the analysis groups
| Total sample, | PIF subsample | Cases, | Matched controls, | Cox model, HR (95% CI), | |
|---|---|---|---|---|---|
| Females | 52.2 (50.9‒54.0) % | 370 (53.3%) | 4 (22.2%) | 20 (27.4%) | – |
| Age | 52.1 (51.7‒52.5) | 52.7 (14.1), 30‒90 | 48.1 (12.2), 30‒71 | 49.1 (10.9), 30‒73 | – |
| Basic education only | 40.8 (39.4‒42.0) % | 291 (41.9%) | 3 (16.7%) | 23 (31.5%) | – |
| Number of siblings | 3.8 (3.7‒3.8) | 3.9 (2.9), 0‒18 | 3.7 (3.1), 0‒10 | 3.5 (2.8), 0‒14 | – |
| Toxo IgG seropositivity | 19.7 (18.3‒21.0) % | 172 (24.8%) | 4 (22.2%) | 15 (20.5%) | 1.91 (0.63, 5.76), 0.250 |
| Toxo IgG antibody level | 27.3 (26.1‒28.5) | 31.0 (31.3), 3.4‒179.4 | 29.2 (30.6), 8.1‒88.4 | 23.6 (25.4), 4.4‒120.7 | 1.01 (1.00, 1.02), 0.128 |
| Toxo IgM seropositivity | N/A | 119 (17.1%) | 4 (25.0%) | 13 (18.3%) | 1.38 (0.37, 5.10), 0.634 |
| Toxo IgM antibody level | N/A | 2.0 (1.0), − 0.1 to 5.0 | 2.1 (1.0), 0.8‒4.0 | 1.9 (1.0), 0.4‒4.4 | 1.14 (0.66, 1.99), 0.643 |
| CMV IgG seropositivity | 83.5 (82.5‒84.0) % | 583 (84.0%) | 15 (83.3%) | 59 (80.8%) | 1.03 (0.30, 3.57), 0.957 |
| CMV IgG antibody level | 4.2 (4.1‒4.3) | 4.2 (2.2), 0.1‒9.9 | 3.4 (1.7), 0.4‒5.7 | 3.6 (2.0), 0.3‒7.6 | 0.89 (0.74, 1.07), 0.238 |
| CMV IgM seropositivity | N/A | 114 (16.4%) | 2 (12.5%) | 6 (8.5%) | 1.24 (0.18, 8.79), 0.828 |
| CMV IgM antibody level | N/A | 2.0 (1.0), 0.7‒6.1 | 1.8 (0.7), 0.8‒3.2 | 1.8 (0.8), 0.8‒4.2 | 0.88 (0.41, 1.89), 0.750 |
| EBV IgG seropositivity | 97.9 (97.5‒98.0) % | 678 (97.7%) | 18 (100%) | 73 (100%) | N/A |
| EBV IgG antibody level | 1.5 (1.4‒1.5) | 1.4 (0.7), 0.1‒4.5 | 1.5 (0.9), 0.4‒3.6 | 1.5 (0.7), 0.4‒3.7 | 0.98 (0.49, 1.96), 0.964 |
| HSV-1 IgG seropositivity | 71.2 (70.0‒72.0) % | 496 (71.5%) | 14 (77.8%) | 47 (64.4%) | 1.69 (0.55, 5.22), 0.360 |
| HSV-1 IgG antibody level | 3.7 (3.7‒3.8) | 3.8 (2.8), 0.1‒16.9 | 3.8 (2.5), 0.2‒8.5 | 3.7 (3.3), 0.2‒12.7 | 1.01 (0.88, 1.15), 0.942 |
HR Hazard Ratio (95% CI, confidence interval), p value for the infection variable
aCalculated with weights to adjust for the oversampling of individuals aged ≥ 80 years and non-response. Prevalences (95% CI), or mean (95% CI). Only IgG levels available from the total sample
bN (%), or mean (SD), range
cSuicide or self-harm diagnosis during the 15-year register follow-up (cases), and the control subjects for them, matched for age, gender, and health center district
dCox regression model predicting case status; adjusting for gender, age, educational level, region of residence, and number of siblings
Linear regression models predicting baseline depressive symptoms (BDI score)
| Beta value | ||
|---|---|---|
| Toxoplasma IgG seropositivity | ||
| Toxoplasma IgG antibody level | 0.01 | 0.060 |
| Toxoplasma IgM seropositivity | 0.80 | 0.421 |
| Toxoplasma IgM antibody level | − 0.23 | 0.546 |
| CMV IgG seropositivity | 0.12 | 0.631 |
| CMV IgG antibody level | 0.02 | 0.588 |
| CMV IgM seropositivity | 0.75 | 0.469 |
| CMV IgM antibody level | 0.17 | 0.669 |
| EBV IgG seropositivity | 0.39 | 0.479 |
| EBV IgG antibody level | − 0.06 | 0.667 |
| HSV-1 IgG seropositivity | 0.11 | 0.600 |
| HSV-1 IgG antibody level | 0.016 | 0.631 |
All models adjusting for gender, age, educational level, region of residence, number of siblings, and IgG analyses also for plate
Association with IgG levels, n = 5786, weighted to adjust for the oversampling of individuals aged ≥ 80 years and non-response. Association with IgM levels, n = 705
Significant values in bold
Logistic regression models predicting lifetime suicidal thoughts and attempts in the PIF subsample (n = 694)
| Suicidal thoughts (no/yes) | Suicide attempts (none/one/multiple) | |||
|---|---|---|---|---|
| OR (95% CI)a | OR (95% CI)b | |||
| Toxo IgG seropositivity | 0.76 (0.50, 1.16) | 0.196 | 0.98 (0.47, 2.08) | 0.966 |
| Toxo IgG antibody level | 1.00 (0.99, 1.00) | 0.125 | 1.00 (0.99, 1.01) | 0.941 |
| Toxo IgM seropositivity | 1.06 (0.67, 1.67) | 0.815 | 0.91 (0.38, 2.16) | 0.828 |
| Toxo IgM antibody level | 1.08 (0.91, 1.29) | 0.379 | 1.03 (0.74, 1.44) | 0.846 |
| CMV IgG seropositivity | 0.85 (0.53, 1.37) | 0.511 | ||
| CMV IgG antibody level | 0.99 (0.91, 1.08) | 0.796 | 0.92 (0.80, 1.07) | 0.289 |
| CMV IgM seropositivity | 0.75 (0.46, 1.24) | 0.261 | 0.61 (0.22, 1.68) | 0.342 |
| CMV IgM antibody level | 0.97 (0.81, 1.16) | 0.713 | 0.87 (0.62, 1.22) | 0.413 |
| EBV IgG seropositivity | 0.60 (0.19, 1.83) | 0.365 | 0.46 (0.92, 2.33) | 0.350 |
| EBV IgG antibody level | 1.01 (0.76, 1.33) | 0.958 | 1.18 (0.72, 1.92) | 0.518 |
| HSV-1 IgG seropositivity | 1.15 (0.77, 1.73) | 0.485 | 0.88 (0.44, 1.75) | 0.716 |
| HSV-1 IgG antibody level | 1.00 (0.94, 1.07) | 0.968 | 0.94 (0.83, 1.06) | 0.331 |
All models adjusting for gender, age, educational level, region of residence, number of siblings, screen status, and IgG analyses also for plate. Significant values in bold
CI confidence interval, OR odds ratio of the seropositivity or antibody level
aOR for suicidal thoughts, the reference category is No suicidal thoughts
bOR for multiple attempts, the reference category is No suicide attempts